Methanol → HCID 86616742, compound
Reaction equation
C[O:2][C:3]1[CH:12]=[C:11]2[C:6]([CH:7]=[CH:8][C:9]([C:13]3[C:21]4[C:16](=[CH:17][CH:18]=[C:19]([NH:22][C:23]5[CH:28]=[CH:27][N:26]=[C:25]([NH2:29])[N:24]=5)[CH:20]=4)[NH:15][N:14]=3)=[CH:10]2)=[CH:5][CH:4]=1.B(Br)(Br)Br.C[OH:35]>C(Cl)Cl.C1COCC1>[C:3]([OH:2])(=[O:35])[CH3:12].[C:3]([OH:2])(=[O:35])[CH3:12].[NH2:29][C:25]1[N:24]=[C:23]([NH:22][C:19]2[CH:20]=[C:21]3[C:16](=[CH:17][CH:18]=2)[NH:15][N:14]=[C:13]3[C:9]2[CH:10]=[C:11]3[C:6]([CH:5]=[CH:4][C:3]([OH:2])=[CH:12]3)=[CH:7][CH:8]=2)[CH:28]=[CH:27][N:26]=1Participants
Reactant 3
Product 1
Reagents, catalysts & solvents 2
Procedure
To a suspension of 4-[3-(7-methoxy-naphthalen-2-yl)-1H-indazol-5-ylamino]-pyrimidine-2-amine (Preparation #28 followed by general procedure N and F, 20 mg, 0.05 mmol) in CH2Cl2 (1 mL) was added 1M BBr3 in THF (1 mL). The mixture was stirred for about 2 hours at room temperature then methanol (1 mL) was added and the mixture concentrated under reduced pressure. The residue was purified by preparative reverse phase HPLC to give 7-[5-(2-amino-pyrimidin-4-ylamino)-1H-indazol-3-yl]-naphthalen-2-ol diacetate (12 mg, 60%); (DMSO-d6, 400 MHz) δ9.08 (s, 1H), 8.35 (s, 1H), 8.30 (s, 1H), 8.03 (d, 1H), 7.89 (d, 1H), 7.80 (m, 2H), 7.72 (d, 1H), 7.53 (d, 1H), 7.16 (s, 1H), 7.11 (d, 1H), 6.06 (bs, 2H), 5.99 (d, 1H), 1.87 (s, 6H); RP-HPLC (Table 1, Method e) Rt 1.43 min; m/z: (M+H)+ 369.2.
Workup
- concentrationthe mixture concentrated under reduced pressure
- customThe residue was purified by preparative reverse phase HPLC
Sources & evidence
- ORD record
- ord-0382dbcd9ee442aa9fa32a6a34f5e64c
- Source dataset
- uspto-grants-2011_08
- Patent number
- US08008481B2
Reaction notes
Loading…